WO2009029141A2 - Methods for modifying electrical currents in neuronal circuits - Google Patents
Methods for modifying electrical currents in neuronal circuits Download PDFInfo
- Publication number
- WO2009029141A2 WO2009029141A2 PCT/US2008/008182 US2008008182W WO2009029141A2 WO 2009029141 A2 WO2009029141 A2 WO 2009029141A2 US 2008008182 W US2008008182 W US 2008008182W WO 2009029141 A2 WO2009029141 A2 WO 2009029141A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fup
- mammal
- brain
- pharmaceutical medication
- target location
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 70
- 230000001537 neural effect Effects 0.000 title claims description 48
- 239000003814 drug Substances 0.000 claims description 59
- 229940079593 drug Drugs 0.000 claims description 58
- 210000004556 brain Anatomy 0.000 claims description 57
- 241000124008 Mammalia Species 0.000 claims description 45
- 238000003384 imaging method Methods 0.000 claims description 31
- 210000001519 tissue Anatomy 0.000 claims description 31
- 238000002604 ultrasonography Methods 0.000 claims description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 18
- 230000000926 neurological effect Effects 0.000 claims description 12
- 238000002610 neuroimaging Methods 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 208000012902 Nervous system disease Diseases 0.000 claims description 8
- 208000025966 Neurological disease Diseases 0.000 claims description 8
- 230000004075 alteration Effects 0.000 claims description 8
- 230000005291 magnetic effect Effects 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 8
- 208000020016 psychiatric disease Diseases 0.000 claims description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 208000015706 neuroendocrine disease Diseases 0.000 claims description 6
- 239000003488 releasing hormone Substances 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 210000003625 skull Anatomy 0.000 claims description 6
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims description 5
- 101800000414 Corticotropin Proteins 0.000 claims description 5
- XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 claims description 5
- 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 claims description 5
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 claims description 5
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 claims description 5
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 5
- 229960000258 corticotropin Drugs 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 230000002267 hypothalamic effect Effects 0.000 claims description 5
- 210000003016 hypothalamus Anatomy 0.000 claims description 5
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims description 5
- 229940034199 thyrotropin-releasing hormone Drugs 0.000 claims description 5
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 4
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 4
- 108010004977 Vasopressins Proteins 0.000 claims description 4
- 102000002852 Vasopressins Human genes 0.000 claims description 4
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 4
- 238000002591 computed tomography Methods 0.000 claims description 4
- 239000003302 ferromagnetic material Substances 0.000 claims description 4
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 4
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims description 4
- 239000000601 hypothalamic hormone Substances 0.000 claims description 4
- 229940043650 hypothalamic hormone Drugs 0.000 claims description 4
- 210000001767 medulla oblongata Anatomy 0.000 claims description 4
- 229960003726 vasopressin Drugs 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 101800000989 Oxytocin Proteins 0.000 claims description 3
- 102400000050 Oxytocin Human genes 0.000 claims description 3
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 3
- 230000037182 bone density Effects 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- 229960003638 dopamine Drugs 0.000 claims description 3
- 230000002757 inflammatory effect Effects 0.000 claims description 3
- 229960003987 melatonin Drugs 0.000 claims description 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 3
- 229960001723 oxytocin Drugs 0.000 claims description 3
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims description 3
- 208000017520 skin disease Diseases 0.000 claims description 3
- 210000002820 sympathetic nervous system Anatomy 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 208000027796 Blood pressure disease Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims description 2
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000019255 Menstrual disease Diseases 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 101710142969 Somatoliberin Proteins 0.000 claims description 2
- 108010056088 Somatostatin Proteins 0.000 claims description 2
- 102000005157 Somatostatin Human genes 0.000 claims description 2
- 208000024799 Thyroid disease Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 208000037824 growth disorder Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 210000001002 parasympathetic nervous system Anatomy 0.000 claims description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 claims description 2
- 208000015891 sexual disease Diseases 0.000 claims description 2
- 229960000553 somatostatin Drugs 0.000 claims description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 2
- 230000002889 sympathetic effect Effects 0.000 claims description 2
- 231100000397 ulcer Toxicity 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 28
- 238000011282 treatment Methods 0.000 description 20
- 230000004048 modification Effects 0.000 description 14
- 238000012986 modification Methods 0.000 description 14
- 230000004913 activation Effects 0.000 description 10
- 238000011491 transcranial magnetic stimulation Methods 0.000 description 10
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 7
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 238000002600 positron emission tomography Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 206010041250 Social phobia Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 208000019906 panic disease Diseases 0.000 description 3
- 208000028173 post-traumatic stress disease Diseases 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000238876 Acari Species 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- BGPVFRJUHWVFKM-UHFFFAOYSA-N N1=C2C=CC=CC2=[N+]([O-])C1(CC1)CCC21N=C1C=CC=CC1=[N+]2[O-] Chemical compound N1=C2C=CC=CC2=[N+]([O-])C1(CC1)CCC21N=C1C=CC=CC1=[N+]2[O-] BGPVFRJUHWVFKM-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 208000022371 chronic pain syndrome Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 230000000955 neuroendocrine Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 210000004560 pineal gland Anatomy 0.000 description 2
- 210000002442 prefrontal cortex Anatomy 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000008454 sleep-wake cycle Effects 0.000 description 2
- 210000004001 thalamic nuclei Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000001943 adrenal medulla Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000401 corticothalamic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940063296 testosterone and estrogen Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N7/02—Localised ultrasound hyperthermia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
- A61B90/36—Image-producing devices or illumination devices not otherwise provided for
- A61B90/37—Surgical systems with images on a monitor during operation
- A61B2090/374—NMR or MRI
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0078—Ultrasound therapy with multiple treatment transducers
Description
METHODS FOR MODIFYING ELECTRICAL CURRENTS IN NEURONAL
CIRCUITS
RELATED APPLICATIONS
[0001] This application is a continuation-in-part application of utility Publication No.
2003/0204135, filed on April 30, 2002.
BACKGROUND
[0002] Field of the Invention
[0003] The present invention relates to methods for medical diagnosis and treatment, and more particularly to methods for diagnosis and treatment of specific psychiatric, neurological and neuroendocrine conditions using a Focused Ultrasonic Pulse (FUP) delivered to different points of neuronal circuits within the brain using existing focused ultrasound devices. The treatment is performed under the guidance of the existing brain- imaging devices, such as functional magnetic resonance imaging (fMRI). [0004] Brief Description of the Prior Art
[0005] With advances in brain imaging techniques, the pathophysiology of psychiatric and medical disorders began to be more and more related to the specific neuronal circuits. Neuronal circuits are specific brain centers functionally and anatomically connected with each other. Usually a circuit involves sub-cortical neuronal centers connected with cortex. It is not totally clear how the circuits operate. However, it is clear that they play a major role in multiple psychiatric, neurological and medical conditions. For example, Obsessive Compulsive Disorder (OCD) and OCD Spectrum Disorders including Impulse Control Disorders appear to be related to abnormality in Orbito-Fronto-Talamic-Striatum circuit. Panic Disorder, Social Anxiety Disorder and panic spectrum disorders seem to be associated with the abnormal functioning of circuit involving Orbital-Frontal cortex, Amygdala, Cingulum and Hippocampus. Post-Traumatic Stress Disorders seem to associate with Prefrontal Cortex, Amydgala and Hippocampus abnormalities. Psychotic disorders
seem to have an association with Prefrontal Cortex - Talamic - Striatum and Occipital
Cortex Circuits. Circuits involved in neurological conditions have also been identified. For example, Parkinsonian Disease, Huntington Chorea, La Touretts and tick syndromes seem to have abnormalities in Cortico-Talamic-Straitum Circuit. Chronic pain has association with cortico-thalamic circuits. Insomnia has association with temporal cortex-lymbic-cingulum circuit. Medical conditions seem to have connection with specific neurocircuitry. For example, obesity and stress are associated with temporal-hypothalamic circuit. For a simple review and description of the above circuits, see Clark, D. L. and Boutros, N.N., Brain and Behavior (1999) and Rauch, S. L. et al., "Clinical Neuroimaging in Psychiatry" in Harvard Review of Psychiatry (1995), Vol. 2, no. 6, pp. 297-312.
[0006] Neuroimaging techniques exist that permit assessment of rapid changes in activity of the brain. Functional Nuclear Magnetic Resonance (fMRI), Vector Electroencephalagraphy (V-EEG) and Positron Emission Tomography (PET) are the most promising. These techniques, specifically fMRI, are capable of producing real time 3- dimensional maps of brain activity. These techniques merit scientists to study the neuronal circuits involved in pathology of different psychiatric or neurological conditions. However, the study process has been slowed by the absence of reliable activation of these circuits. [0007] Recently, a few novel methods of the treatment of mental and neurological disorders directed at neuronal circuits have been introduced. These include deep brain stimulation by implanted electrodes, successfully used in OCD, Parkinson's disease and epilepsy, and brain surgery used in the treatment of OCD and depression. See New England Journal of Medicine (Sept. 27 2001), pp. 656-63; R.M. Roth, et al., Current Psychiatry Report (Oct. 2001), Vol. 3, no. 5, pp. 366-72. Because of the invasiveness and possible complications, these methods are reserved for the treatment resistant conditions where other treatments fail. However, the success of these treatments underlines the importance of specific neurocircuits in the pathophysiology of mental and neurological disorders.
Furthermore, it underlines the importance of developing non-invasive methods of intervention at the neuronal circuit level. In addition, the studies using deep brain stimulation techniques determined that low frequency (2-150 Hz) signals inhibit the neuronal tissue and that high frequency (1-3 MHz) signals stimulate neuronal circuits. [0008] Recently it has been proposed that neuronal circuits can be assessed and modified non-invasively using Transcranial Magnetic Stimulation (TMS). The signal from the brain after the TMS stimulation can be read using MRI. That method has been described in U.S. Patent No. 6,198,958, incorporated herein by reference, which described using the method for therapeutic purposes. The method and device proposed by that patent are currently being implemented in psychiatry and neurology for diagnostic and therapeutic purposes. See M.S. George, et al., Journal of Neuropsychiatry and Clinical Neuroscience (Fall 1996), Vol. 8, no. 4, pp. 373-382. The method, however, has several problems. For example, TMS does not stimulate deep brain centers, because it is incapable of penetrating brain tissue deeper than 1 -2 cm. Also, TMS has a large area of focus, 1 cubic cm or more, which does not permit focused activation of a specific neuronal circuit. Also, there is a problem in using TMS together with fMRI, because TMS produces a magnetic signal that interferes with the magnetic field and consequently with the fMRI image. [0009] Focused ultrasound has been used to modify electrical currents in neuronal tissue. This has been done by a combined application of a magnetic field and an ultrasonic field to neuronal and other tissue in the body. The prior art proposes that modification of electrical currents in neuronal tissue will come from the interaction of the two fields. For example, U.S. Patent No. 4,343,301 describes generating high energy by intersecting two ultrasound beams within any single fixed point of the body, including the skull. While it is not proven that such an application of ultrasound would do anything except heat or destroy tissue, there is recent evidence that application of focused ultrasound to brain slices, subjected to simultaneous electrical stimulation, can change the electrical currents in the
slices. However, because two ultrasound beams cannot be focused within the skull, because of the complexity of bone density and bone structure, it is not possible to focus such a two- beam device in the brain tissue.
[0010] Some companies have produced ultrasonic devices that use multiple beams.
See G.T. Clement, et al., Physics in Medicine and Biology (Dec. 2000), Vol. 45, no. 12, pp. 3707-3719. By coordinating the amplitude and the phase of the ultrasound beams generated by multiple sources via computer multi-beam devices, algorithms can be developed to adjust the bone dispersion of the beam and focus the ultrasound within the brain tissue. These devices are to be used as ultrasonic knives within the brain for the destruction of tumors, for example. However, they cannot be used to modify the electrical and electromagnetic currents within the brain circuits without harming the surrounding tissue.
SUMMARY QF THE INVENTION
[0011 ] It is an object of the invention to provide methods for modifying electrical currents in a live neuronal circuit of a mammal, preferably a human. The modification is accomplished by applying a focused ultrasound pulse (FUP) under the guidance of a brain- imaging system such as a functional magnetic resonance imaging (fMRI) system, a vector- electroencephalograph (V-EEG), or a positron emission tomograph (PET), preferably fMRI. The application of FUP is generally via multiple ultrasound transducers that are housed in a cap worn by a patient. It is simultaneous with the use of the brain-imaging system. The application of different frequencies and phases of FUP to the brain circuits will generate a signal that will be captured by fMRI. At that time, changes in circuits will be assessed. This will permit adjustment of the focus of the FUP and of the location of the FUP, or the use of multiple focuses, to achieve the maximum modification of the circuit. The changes in the circuit are useful for research, diagnosis and treatment.
[0012] In the present embodiments, there is provided a method of treating psychiatric, neurological and neuroendocrine disorders in a mammal through application of FUPs. The treatment is accomplished by applying a focused ultrasound pulse (FUP) to a tissue of the mammal, and the applied FUP uses a variation in frequency to disrupt or activate a tissue function. Monitoring is performed through a tissue image from an imaging system during the application of the FUP. The tissue can be the brain of the mammal or any other body tissue of the mammal.
[0013] It is a further object of the methods to diagnose and treat specific psychiatric, neurological, and neuroendocrine conditions. Examples of such conditions include, but are not limited to, Obsessive Compulsive Disorder and its spectrum, Post Traumatic Stress Disorder, Depression, Bipolar Disorder, Social Anxiety Disorder, Psychotic Disorders, Panic Disorder, Ticks, Chronic Pain Syndrome, Insomnia, Chronic Fatigue Syndrome, Insomnia, Stress and Obesity, and other conditions apparent to one of ordinary skill in the art. [0014] In further embodiments, there is provided a method of treating a mammal comprising the steps of administering a pharmaceutical medication to the mammal, assessing the pharmaceutical medication in the mammal with an imaging system to determine when the pharmaceutical medication distributes to or reaches a target location in the mammal, applying a focused ultrasound pulse (FUP) to the target location in the mammal to alter the pharmaceutical medication at the target location, and assessing the response from to the medication from the target location with an image from the imaging system during the application of the FUP. The alteration may cause a change in property of the pharmaceutical medication, such as for example, the chemical activity, composition and viscosity. In an embodiment, the alteration changes the pharmaceutical medication to an active form. Furthermore, the treatment of applying a FUP to a tissue of the mammal in combination with the administering of a pharmaceutical medication to the mammal and altering the pharmaceutical medication at a target location, all the while assessing the tissue activity
and/or response through the imaging system, provides a novel manner of treating a number of disorders contemplated herein.
BRIEF DESCRIPTION QF THE DRAWINGS
[0015] A detailed description of embodiments of the invention will be made with reference to the accompanying drawings, wherein numerals designate corresponding parts in the several figures.
[0016] FIG. 1 illustrates an FUP device according to one embodiment of the invention. Shown is a modified multi-transducer cap, capable of focusing ultrasound in the skull and delivering the FUP signal to a specific target in the brain.
[0017] FIG. 2 illustrates how the cap of Fig. 1 can be placed on the head of a human subject.
[0018] FIG. 3 illustrates a system in accordance with an embodiment of the present invention in which the FUP device is being used in conjunction with the brain imaging system, here shown as fMRI.
[0019] FIG. 4 illustrates a perspective of the right side of the system shown in FIG. 3, looking down on the head of the human subject.
[0020] FIG. 5 illustrates a system in accordance with an embodiment of the present invention in which the FUP device is being used in conjunction with an imaging system to alter an administered pharmaceutical medication.
DETAILED DESCRIPTION
[0021] FIG. 1 illustrates a preferred embodiment of a focused ultrasound pulse (FUP) device. A cap 1 houses multiple ultrasound transducers 2, preferably 300-1000 transducers. The FUP device is preferably a multi-beam ultrasonic device, which is coordinated via computer with conventional brain-imaging system, such as a focused magnetic resonance imaging (fMRI) system, a vector-electroencephalograph (V-EEG) or a positron emission
tomograph (PET), preferably an fMRI system. An example of a preferable multi-beam ultrasonic device is an ultrasound knife. The transducers are regulated via a computer capable of focusing the ultrasound waves into a specific point 3. The cap and transducers are preferably made from a non-ferromagnetic material, a material that has a very low permeability and residual magnetism and hysterisis, such as copper. The use of a non- ferromagnetic material reduces fMRI field distortion and thereby reduces distortion of the image, permitting the application of FUP concurrently with the use of fMRI. By concurrent, it is meant that one applies an FUP within 1 millisecond to 10 seconds before or after using the fMRI system to image the brain.
[0022] FIG. 2 illustrates how the cap can be placed on the head of a human subject.
A computer, which is coupled to the FUP device, controls the parameters of the FUP, including focus, frequency, phase and amplitude. Through user interaction with the computer, the FUP device is capable of producing a focused ultrasound pulse in a specific point within the brain. The FUP's focus is preferably 2 or more centimeters deep and 0.5- 1000 mm in diameter, and more preferably 2-12 cm deep and 0.5-2 mm in diameter. The specific point is determined by a conventional brain-imaging system, preferably an fMRI system, which provides information about brain form and density. FUP software is preferably coordinated with fMRI software for precise positioning and coordination of the focused signal. The changes in activity within the neuronal circuits are determined by monitoring the changes in the brain image produced by the fMRI before the application of FUP and during and after the application of FUP. These changes are used to determine exactly where the FUP focus was in the brain and the functional connectivity between the focus and surrounding brain centers. The specific point may be confirmed using the addition of a computed tomography (CT) scan, which provides information about bone density and structure of the skull and brain. The focus of the FUP may then be modified to direct it into a different point of the brain.
[0023] A single FUP may be applied to a single live neuronal circuit. Multiple FUPs may be applied to the same live neuronal circuit. Additionally, a single FUP may be applied to multiple live neuronal circuits, and multiple FUPs may be applied to multiple live neuronal circuits.
[0024] FUP given in different frequency, phase and amplitude will produce different effects on neuronal circuits and centers. Low frequencies, below 300 Hz, will decrease the firing of the centers and inhibit or disrupt the neuronal circuits. High frequencies, 500 Hz to 5 MHz, will produce activation of firing of neuronal centers and activation of the circuits. In either case, the FUP will modify physiological properties in the circuits. This will happen both when the FUP is applied to the centers and when the FUP is applied to the white matter. [0025] Repeated application of the FUP to neuronal circuits will cause long-term or permanent changes to the circuits. The modification of the circuits using FUP will be used for the treatment of psychiatric, neurological and neuroendocrine disorders. Examples of such diseases include, but are not limited to, Obsessive Compulsive Disorder (and its spectrum), Post Traumatic Stress Disorder, Depression, Bipolar Disorder, Social Anxiety Disorder, Psychotic Disorders, Panic Disorder, Ticks, Chronic Pain Syndrome, Insomnia, Chronic Fatigue Syndrome, Insomnia, Stress, Obesity, and other conditions apparent to one of ordinary skill in the art. This will be done by repeated assessment and modification of changes in neuronal flow or field activity under the guidance of specific brain imaging techniques, such as fMRI, V-EEG, or PET.
[0026] In one embodiment, there is provided a method of treating psychiatric, neurological and neuroendocrine disorders in a mammal by applying a focused ultrasound pulse (FUP) to a tissue of the mammal, and the applied FUP uses a variation in frequency to disrupt or activate a tissue function, and monitoring the tissue through a tissue image from an imaging system during the application of the FUP. The tissue can be that in the brain or another portion of the body. In specific embodiments, the tissue is that of a brain region such
as the hypothalamus or medulla oblongata. In such embodiments, the applied FUP uses a low frequency to disrupt the neuronal circuits or a high frequency to activate the neuronal circuits of the brain region such that the disruption or activation results in a modulation of a bodily reaction. The FUP application and the modulation can be monitored through a brain image from the imaging system. The application of FUP may also be applied to at least one other live neuronal circuit within the brain region concurrently. [0027] Application of FUP to the hypothalamus, and more specifically to a hypothalamic nuclei, can modify the release of natural hormones and cause either an increase or decrease in release of a hypothalamic hormone. The hypothalamic hormone can be any of the following: corticotrophin-releasing hormone (CRH), dopamine, gonadotropin-releasing hormone, growth hormone-releasing hormone, melatonin, oxytocin, somatostatin, thyrotropin-releasing hormone, vasopressin, and mixtures thereof. The hypothalamic nuclei can be from the anterior nuclei, tuberal nuclei or posterior nuclei. The modification of release of natural hormones can help treat a number of disorders such as sexual disorder, menstrual disorder, diabetes, growth disorder, blood pressure disorder, thyroid disorder, skin disorder, and wake sleep cycle disorder. Gonadotropin-releasing hormone (GnRH), for example, can cause increases in testosterone and estrogen in males and females, which in turn can increase sexual desire, cause loss of weight, increase energy and decrease anxiety and depression. Increase in estrogen can also prevent osteoporosis, improve physiological and psychological symptoms associated with menstrual dysfunctions. Increase in growth hormone can help increase and improve the energy and height of people, as well as delay aging. Changes in Antidiuretic hormone (ADH) and Oxytocin can modify blood pressure and electrolyte imbalance. Thyrotropin-releasing hormone (TRH) regulates the release of thyroid hormone and modification of TRH levels can help in treatment of symptoms of hyper and hypo-thyroidism.
[0028] Neuroendocrine-immune interactions are regulated by CRH indirectly, through activation of a global stress response, and directly, through pro-inflammatory actions on peripheral immune functions. Neuroimmunological data have demonstrated that CRH activation of the sympathetic nervous system is essential in mediating the link between the brain and immune function. CRH is distributed in the brain and spinal cord, adrenal medulla, testes, ovaries, gastrointestinal tract, pancreas, myometrium, endometrium, placenta, and diverse inflammatory sites. Traditionally, hypothalamic CRH has been considered to act indirectly in an anti-inflammatory fashion, since the end product of the hypothalamic- pituitary-adrenal axis is Cortisol, a well-known anti-inflammatory compound. Thus, activation of CRH will influence immunity and can treat immunological disorders without the negative side effects of external or synthetic hormonal therapy. A modification of the release of corticotrophin-releasing hormone wherein the hormone is increased may be used to treat a number of immunological disorders. It is also contemplated, however, that a decrease in CRH may help treat other disorders. For example, where the release of corticotrophin- releasing hormone is decreased, this may help treat opportunistic inflammations and fungal infections as well as beneficially affect some forms of cancer.
[0029] Application of FUP to the medulla oblongata can modulate an effect on the sympathetic or parasympathetic nervous system. This embodiment may be used to treat peripheral neuronal disorders such as bowel disorders, ulcers, inflammatory bowel syndrome disorder, irritable bowel syndrome disorder, arrhythmia, and high blood pressure [0030] The supra thalamic nuclei inputs into the pineal gland and can modify the level of melatonin, the hormone that regulates pigmentation of the skin and the sleep wake cycle. Modification of the pineal gland through FUP application to the supra thalamic nuclei may normalize sleep-wake cycle and treat some skin disorders such as excessive pigmentation.
[0031] FIG. 3 illustrates the FUP being used in conjunction with a fMRI system. The fMRI system is preferably a typical GE build cylindrical magnet 4. The patient 5 preferably lies on a sliding platform 6 inside of the magnetic cavity 7. The imaging coil 8, which has been placed over the head of the patient, detects the magnetic resonance field generated by rotation of the magnet 4. The field signals detected by the imaging coil are preferably transmitted to the processing electronics outside the magnet. As a result of the fMRI system's computer analysis, a functional image of the brain is generated. [0032] FIG. 4 illustrates a cross-sectional view of FIG. 3, from a perspective looking down on the head of the patient, as shown by reference numeral 10 in FIG. 3. The cap 1 containing the FUP transducers 2 is preferably on the head of the patient. The imaging coil 8 is preferably placed above the FUP cap. A cable 9 connects the FUP cap with the transducers to the computer, which is kept outside of the room, controlling the FUP. The FUP device is also connected to MRI processing electronics. The FUP device generates FUP pulses that cause activation or deactivation of specific neuronal centers or circuits. The fMRI signal is modified in specific locations. This modification is captured and used to adjust the FUP transducers to achieve better focus, different position, or different influence on the neuronal circuit by modification of the frequency of the waves, frequency of the pulse, intensity of the pulse, or the phase of the waves.
[0033] FIG. 5 illustrates a system in accordance with an embodiment of the present invention in which the FUP device 20 is being used in conjunction with an imaging system 22 to alter an administered pharmaceutical medication 24 and assess a bodily reaction from the altered pharmaceutical medication. In this embodiment, a method of treatment is provided in which a pharmaceutical medication 24 is administered to the mammal 26, for example, through ingestion or injection. The pharmaceutical medication 24 is allowed to distribute to a target location 28 in the mammal 26, for example, a focal point in the brain. The target location can be the brain of the mammal or any other body tissue of the mammal.
[0034] Once it is determined that the medication 24 has distributed to the target location 28, a FUP 30 is applied to the target location 28 in the mammal 26 to alter the pharmaceutical medication 24. The alteration of medication during and after the application of the FUP 30 can be assessed with images from an imaging system 22. The imaging system may be selected from the group consisting of a functional magnetic resonance image (fMRI) system; a vector -electroencephalogram (V-EEG), and a positron emission tomography (PET). For example, in one embodiment, the pharmaceutical medication is administered to a subject in a non-toxic or non-active form. The medication is allowed to distribute and once the target location is reached, the FUP is applied to the focal point to alter the pharmaceutical medication. In embodiments, imaging techniques can be used to monitor and/or guide the medication as it reaches a target location or specific focal point, be it in the brain or another body tissue. One or more FUPs may be applied as needed and the alteration of the medication may be assessed through the imaging system. The frequency and phase of the FUP may also be changed to change the focus of any subsequently applied FUPs at the target location. Bodily reactions to the pharmaceutical medication after the applied FUP at the target location are assessed with an image from the imaging system.
[0035] The alteration causes a change in property of the pharmaceutical medication — the property selected, for example, from the group consisting of chemical activity, composition and viscosity. In a particular embodiment, the alteration activates the pharmaceutical medication. By activating the medication with FUP once it is at a specific focal point in the body, specific medication that could not otherwise access the focal point without harmful effects can do so more safely. For example, an anti-cancer drug can be injected or orally ingested in non-active and non-toxic form. Subsequently, the drug can be activated once it is delivered precisely to the location of the brain tumor. FUP application is then used to alter the drug into an activate form, thus avoiding the toxicity from the drug in other parts of the body. The delivery and effect of the drug can be observed on the imaging.
Similarly, a Parkinson patient can be administered a medication, such as a dopamine activating peptide, in an inactive form and subsequently activated using FUP near basal ganglia circuits causing effect only in that location. This manner of delivery will permit relieving the symptoms without suffering the usual side effects of dopaminergic drugs. In another example, the method may be used to deliver medication across the blood/brain barrier. Many substances cannot bypass the blood-brain barrier. Certain proteins such as liposomal proteins, however, can bypass the blood-brain barrier, so by covering a pharmaceutical medication with the protein, the medication can pass through the barrier. Once the medication has passed through the barrier, applied FUP can be used to destroy the liposomal protein. Moreover, this method can be used for drug delivery or activation within the brain or within any other tissue in the body.
[0036] Mechanical forces produced by frequency 300 Hz or higher can change properties of chemical substances within the FUP focus. These properties include, for example, a change in chemical activity, composition or viscosity. In particular, application of FUP at this frequency range can change the chemical structure by splitting the chemical structure, such as that of protein, RNA, DNA or peptides, into an active and inactive form. The change in the chemical properties or activity can be effected at the target location and can be assessed through imaging. The reaction of the tissue, neuronal centers or neuronal circuits to chemical substance activated by FUP will also be observed on the imaging. [0037] The use of FUP in combination with fMRI or other imaging devices can provide a variety of diagnostic, research and therapeutic benefits. The invention can be used to create a functional map of the brain in response to modification of the neuronal circuits. It can also allow one to observe the functional connectivity within the brain of normal subjects as well as in the brain of the subjects suffering from various neurological conditions, such as the ones identified above. The present embodiments can also be used treat these conditions, and may be used concurrently with the pharmaceutical agents commonly prescribed for them.
For example, the treatment of applying a FUP to a tissue of the mammal in combination with the administering of a pharmaceutical medication to the mammal and altering the pharmaceutical medication at a target location, all the while assessing the tissue activity and/or response through the imaging system, provides a novel manner of treating a number of disorders contemplated herein.
[0038] Development of the functional brain maps can significantly improve our understanding of the operation of the brain in normal subjects and in different diseased states. Unlike the use of transcranial magnetic stimulation (TMS), which can only read a brain tissue depth of about 1 to 2 cm, the FUP is able to reach brain tissue much deeper, 2 or more centimeters into the brain, for example, from about 2 to about 12 cm. Furthermore, the FUP can also produce a focus of energy that will be only from about 0.5 to about 2 mm in diameter, as opposed to about 2-3 cm. attainable by TMS.
[0039] The present embodiments can be used for the evaluation of the outcome of a variety of treatments. For example, the functional maps of the brain, such as those mapping functions of different areas of the brain after application of the FUP, may be constructed using fMRI before and after a particular treatment. If after the treatment the functional reactivity of a certain neuronal circuit becomes similar to that of normal controls, then that may be an indicator of the efficacy of a treatment. In the same way, the present embodiments can be used to determine when the activity of the certain neuronal areas reaches a specific level. The repeated application of FUP may modify the circuits in such a way that their functionality becomes the same as in normal subjects. Repeated application together with continuous fMRI monitoring may help to determine the most efficient, reliable and fast ways to achieve the normalization of neuronal structure and neuronal circuit function. As such, the present embodiments may make the FUP more efficient by determining the best phase, intensity and frequency of the pulse, as well as the best position of the focus or multiple focuses for diagnosis and treatment of the above-mentioned conditions.
[0040] In addition, the present embodiments can be used for the development of pharmaceuticals. For example, the functional maps of the brain could be created using fMRI before, during, and after a particular pharmaceutical is administered to a patient. If, after administration of the pharmaceutical, the functional reactivity of a certain neuronal circuit becomes similar to that of normal controls, then that may be an indicator of the efficacy of the medication.
[0041 ] While the description above refers to particular embodiments of the present invention, it will be understood that many modifications may be made without departing from the spirit thereof. The accompanying claims are intended to cover such modifications as would fall within the true scope and spirit of the present invention. [0042] The presently disclosed embodiments are therefore to be considered in all respects illustrative and not restrictive, the scope of the invention being indicated by the appended claims, rather than the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are therefore intended to be embraced therein.
Claims
1. A method of treating psychiatric, neurological and neuroendocrine disorders in a mammal, the method comprising the steps of: applying a focused ultrasound pulse (FUP) to a tissue of a mammal, and the applied FUP uses a variation in frequency to disrupt or activate a tissue function such that a hormone level is modulated; and monitoring a tissue image from an imaging system during the application of the FUP.
2. The method of claim 1 , wherein the mammal is a human.
3. The method of claim 1 , wherein the tissue is a brain of the mammal.
4. The method of claim 3, wherein the FUP is applied to a live neuronal circuit within a brain region of the mammal, the brain region being selected from the group consisting of a hypothalamus and a medulla oblongata, and the applied FUP uses a low frequency to disrupt the neuronal circuits or a high frequency to activate the neuronal circuits, and wherein the brain image is monitored from the imaging system during the application of the FUP.
5. The method of claim 4, wherein the FUP is applied to the hypothalamus and the modulation is an increase or decrease in release of a hypothalamic hormone.
6. The method of claim 5, wherein the disorders are selected from the group consisting of sexual disorder, menstrual disorder, diabetes, growth disorder, blood pressure disorder, thyroid disorder, skin disorder, and wake sleep cycle disorder.
7. The method of claim 4, wherein the FUP is applied to a hypothalamic nuclei in the hypothalamus, the hypothalamic nuclei being selected from the group consisting of an anterior nuclei, a tuberal nuclei and a posterior nuclei.
8. The method of claim 4, wherein the hypothalamic hormone is selected from the group consisting of corticotrophin-releasing hormone, dopamine, gonadotropin-releasing hormone, growth hormone-releasing hormone, melatonin, oxytocin, somatostatin, thyrotropin-releasing hormone, vasopressin, and mixtures thereof.
9. The method of claim 8, wherein the release of corticotrophin-releasing hormone is increased.
10. The method of claim 9, wherein the disorders are selected from the group consisting of rheumatoid arthritis, ulcerative colitis, lupus, and myelofibrosis.
11. The method of claim 8, wherein the release of corticotrophin-releasing hormone is decreased.
12. The method of claim 11, wherein the disorders are selected from the group consisting of cancer, opportunistic inflammations and fungal infections.
13. The method of claim 4, further comprising the step of: applying at least one additional FUP to at least one other live neuronal circuit within the brain region.
14. The method of claim 4, wherein the FUP is applied to the medulla oblongata and the modulation is an effect on the sympathetic or parasympathetic nervous system.
15. The method of claim 14, wherein the disorders are selected from the group consisting of bowel disorders, ulcers, inflammatory bowel syndrome disorder, irritable bowel syndrome disorder, arrhythmia, and high blood pressure.
16. The method of claim 1, wherein the imaging system is selected from the group consisting of a functional magnetic resonance image (fMRI) system; a vector - electroencephalogram (V-EEG), and a positron emission tomograph (PET).
17. The method of claim 1 , further comprising the step of: administering a pharmaceutical medication to the mammal; and assessing the tissue image from the imaging system after the administration of the pharmaceutical medication.
18. A method of treating psychiatric, neurological and neuroendocrine disorders in a mammal, the method comprising the steps of: administering a pharmaceutical medication to a mammal; allowing the pharmaceutical medication to distribute to a target location in the mammal; applying a focused ultrasound pulse (FUP) to the target location in the mammal to alter the pharmaceutical medication at the target location; and assessing a response to the pharmaceutical medication from the mammal with an image from an imaging system after the application of the FUP.
19. The method of claim 18 further including monitoring the pharmaceutical medication in the mammal with the imaging system to determine when the pharmaceutical medication is distributed to the target location in the mammal.
20. The method of claim 18, wherein the mammal is human.
21. The method of claim 18, wherein the target location is a brain of the mammal.
22. The method of claim 18, wherein the target location is a body tissue of the mammal.
23. The method of claim 18, wherein the alteration causes a change in property of the pharmaceutical medication, the property selected from the group consisting of chemical activity, composition and viscosity.
24. The method of claim 23, wherein the alteration activates the pharmaceutical medication.
25. The method of claim 18, wherein the administration of the pharmaceutical medication to the target location is guided by images from the imaging system.
26. The method of claim 18, wherein the imaging system is selected from the group consisting of a functional magnetic resonance image (fMRI) system; a vector - electroencephalogram (V-EEG), and a positron emission tomograph (PET).
27. The method of claim 18, wherein the step of applying FUP further comprises the step of applying FUP via ultrasound transducers that comprise a non-ferromagnetic material.
28. The method of claim 28, wherein the ultrasound transducers comprise copper.
29. The method of claim 28, wherein there are 300 to 1000 ultrasound transducers.
30. The method of claim 28, wherein the ultrasound transducers are housed in a cap which comprises a non-ferromagnetic material.
31. The method of claim 30, wherein the step of applying FUP further comprises placing the cap on the head of the mammal.
32. The method of claim 30, wherein the cap comprises copper.
33. A method of treating psychiatric, neurological and neuroendocrine disorders in a mammal, the method comprising the steps of: applying a focused ultrasound pulse (FUP) to a live neuronal circuit, where the applied FUP uses a low frequency to disrupt the neuronal circuits or a high frequency to activate the neuronal circuits; monitoring a brain image from a brain imaging system during the application of the FUP; administering a pharmaceutical medication to the mammal; allowing the pharmaceutical medication to distribute to a target location in the brain of the mammal; applying a second FUP to the target location in the mammal to alter the pharmaceutical medication at the target location; and assessing a response to the pharmaceutical medication from the mammal with the brain image from the imaging system after the application of the second FUP.
34. The method of claim 33 further including monitoring the pharmaceutical medication in the mammal with the imaging system to determine when the pharmaceutical medication is distributed to the target location in the mammal.
35. The method of claim 33, wherein the focus of the FUP is about 2 or more centimeters into the brain from the exterior of the skull.
36. The method of claim 33, wherein the focus of the FUP is from about 2 cm to about 12 cm into the brain from the exterior of the skull.
37. The method of claim 33, wherein the frequency of the FUP is less than 300 Hz.
38. The method of claim 33, wherein the frequency of the FUP is from about 500 Hz to about 5 MHz.
39. The method of claim 33, wherein a diameter of the focus area of the FUP is about 0.5 mm.
40. The method of claim 33, further comprising the steps oft adjusting a frequency and phase of the second FUP to change the focus of the second FUP; and applying a third FUP to the target location.
41. The method of claim 33, further comprising the step of running a pre-timed computed tomography (CT) scan to determine bone density and structure of bone surrounding the brain.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/895,687 | 2007-08-27 | ||
US11/895,687 US8086296B2 (en) | 2002-04-30 | 2007-08-27 | Methods for modifying electrical currents in neuronal circuits |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009029141A2 true WO2009029141A2 (en) | 2009-03-05 |
Family
ID=39766963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/008182 WO2009029141A2 (en) | 2007-08-27 | 2008-07-01 | Methods for modifying electrical currents in neuronal circuits |
Country Status (2)
Country | Link |
---|---|
US (1) | US8086296B2 (en) |
WO (1) | WO2009029141A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019042265A1 (en) * | 2017-08-26 | 2019-03-07 | ZHONG, Daiyun | Method and apparatus of modulating neuronal firing frequency at brain functional site in brain |
US11253729B2 (en) | 2016-03-11 | 2022-02-22 | Sorbonne Universite | External ultrasound generating treating device for spinal cord and/or spinal nerve treatment, apparatus comprising such device and method |
US11420078B2 (en) | 2016-03-11 | 2022-08-23 | Sorbonne Universite | Implantable ultrasound generating treating device for spinal cord and/or spinal nerve treatment, apparatus comprising such device and method |
US11738214B2 (en) | 2014-12-19 | 2023-08-29 | Sorbonne Universite | Implantable ultrasound generating treating device for brain treatment, apparatus comprising such device and method implementing such device |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9592409B2 (en) * | 2002-04-30 | 2017-03-14 | The Regents Of The University Of California | Methods for modifying electrical currents in neuronal circuits |
US20040116799A1 (en) * | 2002-11-29 | 2004-06-17 | Ravi Srinivasan | Compatibility of accessory to magnetic resonance |
US8112155B2 (en) * | 2004-02-05 | 2012-02-07 | Motorika Limited | Neuromuscular stimulation |
WO2006096755A2 (en) * | 2005-03-07 | 2006-09-14 | The Brigham And Women's Hospital, Inc. | Adaptive ultrasound delivery system |
US8718758B2 (en) * | 2006-06-19 | 2014-05-06 | Highland Instruments, Inc. | Interface apparatus for stimulation of biological tissue |
US8892200B2 (en) | 2006-06-19 | 2014-11-18 | Highland Instruments, Inc. | Systems and methods for stimulating tissue using focused energy |
US9913976B2 (en) | 2006-06-19 | 2018-03-13 | Highland Instruments, Inc. | Systems and methods for stimulating and monitoring biological tissue |
AU2007261108A1 (en) | 2006-06-19 | 2007-12-27 | Highland Instruments, Inc. | Apparatus and method for stimulation of biological tissue |
US20100174559A1 (en) * | 2006-07-21 | 2010-07-08 | Mcfaul William J | Method and system for providing neuron conditioning |
EP3431138B1 (en) * | 2008-04-30 | 2024-01-24 | Implantica Patent Ltd. | Brain stimulation |
EP2310094B1 (en) | 2008-07-14 | 2014-10-22 | Arizona Board Regents For And On Behalf Of Arizona State University | Devices for modulating cellular activity using ultrasound |
KR101143645B1 (en) * | 2009-07-29 | 2012-05-09 | 주세은 | Transcranial low-intensity ultrasound delivery device and non-invasive modulation of brain function |
CA2779842C (en) * | 2009-11-04 | 2021-06-22 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Devices and methods for modulating brain activity |
US20110190668A1 (en) * | 2010-02-03 | 2011-08-04 | Mishelevich David J | Ultrasound neuromodulation of the sphenopalatine ganglion |
US8956277B2 (en) * | 2010-02-28 | 2015-02-17 | David J. Mishelevich | Stimulation method via deep brain stimulation |
US20110178442A1 (en) * | 2010-01-18 | 2011-07-21 | Mishelevich David J | Patient feedback for control of ultrasound deep-brain neuromodulation |
US20110112394A1 (en) * | 2009-11-11 | 2011-05-12 | Mishelevich David J | Neuromodulation of deep-brain targets using focused ultrasound |
US20140343463A1 (en) * | 2013-05-20 | 2014-11-20 | David J. Mishelevich | Ultrasound neuromodulation treatment of clinical conditions |
US20110130615A1 (en) * | 2009-12-02 | 2011-06-02 | Mishelevich David J | Multi-modality neuromodulation of brain targets |
WO2011101039A1 (en) | 2010-02-22 | 2011-08-25 | Universite Pierre Et Marie Curie (Paris 6) | Apparatus for the treatment of brain affections and method implementing thereof |
KR101999078B1 (en) | 2010-06-09 | 2019-07-10 | 리전츠 오브 더 유니버스티 오브 미네소타 | Dual mode ultrasound transducer (dmut) system and method for controlling delivery of ultrasound therapy |
US20140148726A1 (en) | 2010-10-21 | 2014-05-29 | Timothy Andrew WAGNER | Methods for detecting a condition |
KR102006035B1 (en) | 2011-04-14 | 2019-07-31 | 리전츠 오브 더 유니버스티 오브 미네소타 | Vascular characterization using ultrasound imaging |
EP2736468B1 (en) | 2011-07-27 | 2016-04-27 | Université Pierre et Marie Curie (Paris 6) | Device for treating the sensory capacity of a person |
US8594783B2 (en) | 2011-08-24 | 2013-11-26 | Highland Instruments, Inc. | Systems and methods for stimulating cellular function in tissue |
WO2013059833A1 (en) | 2011-10-21 | 2013-04-25 | Neurotrek, Inc. | Method and system for direct communication |
US20130197401A1 (en) | 2011-12-30 | 2013-08-01 | Tomo Sato | Optimization of ultrasound waveform characteristics for transcranial ultrasound neuromodulation |
US11167154B2 (en) | 2012-08-22 | 2021-11-09 | Medtronic, Inc. | Ultrasound diagnostic and therapy management system and associated method |
WO2014036170A1 (en) | 2012-08-29 | 2014-03-06 | Thync, Inc. | Systems and devices for coupling ultrasound energy to a body |
CN104955388B (en) * | 2012-11-13 | 2018-12-25 | 艾欧敏达有限公司 | The neurophysiological data analysis divided using space-time |
US9440070B2 (en) | 2012-11-26 | 2016-09-13 | Thyne Global, Inc. | Wearable transdermal electrical stimulation devices and methods of using them |
US9399126B2 (en) | 2014-02-27 | 2016-07-26 | Thync Global, Inc. | Methods for user control of neurostimulation to modify a cognitive state |
CN103830841B (en) | 2012-11-26 | 2018-04-06 | 赛威医疗公司 | Wearable endermic electrical stimulation apparatus and its application method |
US10512794B2 (en) | 2016-12-16 | 2019-12-24 | Brainsonix Corporation | Stereotactic frame |
US10974078B2 (en) | 2012-12-27 | 2021-04-13 | Brainsonix Corporation | Treating degenerative dementia with low intensity focused ultrasound pulsation (LIFUP) device |
US9061133B2 (en) | 2012-12-27 | 2015-06-23 | Brainsonix Corporation | Focused ultrasonic transducer navigation system |
CN105934261B (en) | 2013-06-29 | 2019-03-08 | 赛威医疗公司 | For changing or induction cognitive state transcutaneous electrostimulation device and method |
EP3025166B1 (en) | 2013-07-23 | 2020-06-17 | Regents of the University of Minnesota | Ultrasound image formation and/or reconstruction using multiple frequency waveforms |
US9713433B2 (en) | 2013-11-13 | 2017-07-25 | Elminda Ltd. | Method and system for managing pain |
US9333334B2 (en) | 2014-05-25 | 2016-05-10 | Thync, Inc. | Methods for attaching and wearing a neurostimulator |
USD759803S1 (en) | 2014-10-28 | 2016-06-21 | Highland Instruments, Inc. | Adjustable headpiece with anatomical markers |
US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
US11458337B2 (en) | 2017-11-28 | 2022-10-04 | Regents Of The University Of Minnesota | Adaptive refocusing of ultrasound transducer arrays using image data |
US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
US11596812B2 (en) | 2018-04-06 | 2023-03-07 | Regents Of The University Of Minnesota | Wearable transcranial dual-mode ultrasound transducers for neuromodulation |
US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
CN113382683A (en) | 2018-09-14 | 2021-09-10 | 纽罗因恒思蒙特实验有限责任公司 | System and method for improving sleep |
US20200246640A1 (en) * | 2019-01-31 | 2020-08-06 | Synaptec Network, Inc. | Systems and methods for using low intensity ultrasonic transducer on the brain |
US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
US11759661B2 (en) | 2020-05-20 | 2023-09-19 | Brainsonix Corporation | Ultrasonic transducer treatment device |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4343301A (en) | 1979-10-04 | 1982-08-10 | Robert Indech | Subcutaneous neural stimulation or local tissue destruction |
US6088613A (en) * | 1989-12-22 | 2000-07-11 | Imarx Pharmaceutical Corp. | Method of magnetic resonance focused surgical and therapeutic ultrasound |
US5291890A (en) | 1991-08-29 | 1994-03-08 | General Electric Company | Magnetic resonance surgery using heat waves produced with focussed ultrasound |
US5247935A (en) | 1992-03-19 | 1993-09-28 | General Electric Company | Magnetic resonance guided focussed ultrasound surgery |
US5275165A (en) | 1992-11-06 | 1994-01-04 | General Electric Company | Magnetic resonance guided ultrasound therapy system with inclined track to move transducers in a small vertical space |
EP0617982A1 (en) | 1993-03-11 | 1994-10-05 | Zentralinstitut Für Biomedizinische Technik Universität Ulm | Method and apparatus for neuromagnetical stimulation |
US5307812A (en) | 1993-03-26 | 1994-05-03 | General Electric Company | Heat surgery system monitored by real-time magnetic resonance profiling |
DE69634714T2 (en) | 1995-03-31 | 2006-01-19 | Kabushiki Kaisha Toshiba, Kawasaki | Therapeutic ultrasound device |
US6094598A (en) | 1996-04-25 | 2000-07-25 | Medtronics, Inc. | Method of treating movement disorders by brain stimulation and drug infusion |
US7505807B1 (en) * | 1997-05-15 | 2009-03-17 | Regents Of The University Of Minnesota | Magnetic resonance apparatus for use with active electrode and drug deliver catheter |
US6231516B1 (en) * | 1997-10-14 | 2001-05-15 | Vacusense, Inc. | Endoluminal implant with therapeutic and diagnostic capability |
US6066123A (en) * | 1998-04-09 | 2000-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of bioavailability by use of focused energy delivery to a target tissue |
US6198958B1 (en) | 1998-06-11 | 2001-03-06 | Beth Israel Deaconess Medical Center, Inc. | Method and apparatus for monitoring a magnetic resonance image during transcranial magnetic stimulation |
US6309355B1 (en) * | 1998-12-22 | 2001-10-30 | The Regents Of The University Of Michigan | Method and assembly for performing ultrasound surgery using cavitation |
JP2002534218A (en) * | 1999-01-15 | 2002-10-15 | ライト サイエンシーズ コーポレイション | Non-invasive vascular therapy |
US6198956B1 (en) | 1999-09-30 | 2001-03-06 | Oti Ophthalmic Technologies Inc. | High speed sector scanning apparatus having digital electronic control |
US6612988B2 (en) | 2000-08-29 | 2003-09-02 | Brigham And Women's Hospital, Inc. | Ultrasound therapy |
US6348793B1 (en) * | 2000-11-06 | 2002-02-19 | Ge Medical Systems Global Technology, Company, Llc | System architecture for medical imaging systems |
-
2007
- 2007-08-27 US US11/895,687 patent/US8086296B2/en not_active Expired - Fee Related
-
2008
- 2008-07-01 WO PCT/US2008/008182 patent/WO2009029141A2/en active Application Filing
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11738214B2 (en) | 2014-12-19 | 2023-08-29 | Sorbonne Universite | Implantable ultrasound generating treating device for brain treatment, apparatus comprising such device and method implementing such device |
US11253729B2 (en) | 2016-03-11 | 2022-02-22 | Sorbonne Universite | External ultrasound generating treating device for spinal cord and/or spinal nerve treatment, apparatus comprising such device and method |
US11420078B2 (en) | 2016-03-11 | 2022-08-23 | Sorbonne Universite | Implantable ultrasound generating treating device for spinal cord and/or spinal nerve treatment, apparatus comprising such device and method |
US11771925B2 (en) | 2016-03-11 | 2023-10-03 | Sorbonne Universite | Implantable ultrasound generating treating device for spinal cord and/or spinal nerve treatment, apparatus comprising such device and method |
WO2019042265A1 (en) * | 2017-08-26 | 2019-03-07 | ZHONG, Daiyun | Method and apparatus of modulating neuronal firing frequency at brain functional site in brain |
CN110831491A (en) * | 2017-08-26 | 2020-02-21 | 李小平 | Method and apparatus for actively sensing neuron firing frequency at functional site in brain |
Also Published As
Publication number | Publication date |
---|---|
US8086296B2 (en) | 2011-12-27 |
US20070299370A1 (en) | 2007-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8086296B2 (en) | Methods for modifying electrical currents in neuronal circuits | |
US20210386293A1 (en) | Methods and systems for modifying electrical currents in neuronal circuits | |
US7283861B2 (en) | Methods for modifying electrical currents in neuronal circuits | |
US9089683B2 (en) | Neuromodulation method via deep-brain stimulation | |
Jones et al. | Three-dimensional transcranial microbubble imaging for guiding volumetric ultrasound-mediated blood-brain barrier opening | |
Huang et al. | Opening the blood-brain barrier with MR imaging–guided focused ultrasound: Preclinical testing on a trans–human skull porcine model | |
Rezayat et al. | A review on brain stimulation using low intensity focused ultrasound | |
Fishman et al. | Focused ultrasound: an emerging therapeutic modality for neurologic disease | |
Martin et al. | High‐intensity focused ultrasound for noninvasive functional neurosurgery | |
O'Reilly et al. | Investigation of the safety of focused ultrasound-induced blood-brain barrier opening in a natural canine model of aging | |
Bauer et al. | Noninvasive functional neurosurgery using transcranial MR imaging-guided focused ultrasound | |
Jones et al. | Ultrafast three-dimensional microbubble imaging in vivo predicts tissue damage volume distributions during nonthermal brain ablation | |
US20080033297A1 (en) | Neural tissue stimulation, assessment, mapping, and therapy utilizing targeted acoustic mechanisms | |
US20110208094A1 (en) | Ultrasound neuromodulation of the reticular activating system | |
Yoo | Technical review and perspectives of transcranial focused ultrasound brain stimulation for neurorehabilitation | |
Kondziolka et al. | Stereotactic radiosurgery for epilepsy and functional disorders | |
Todd et al. | Targeted manipulation of pain neural networks: The potential of focused ultrasound for treatment of chronic pain | |
Martin et al. | Focused ultrasound surgery of the brain | |
Webb et al. | Remus: System for remote deep brain interventions | |
Pang et al. | Ultrasound deep brain stimulation modulates body temperature in mice | |
Olmstead et al. | Transcranial and pulsed focused ultrasound that activates brain can accelerate remyelination in a mouse model of multiple sclerosis | |
EP3426157B1 (en) | External ultrasound generating treating device for spinal cord and spinal nerves treatment | |
Jolesz et al. | MRI-guided focused ultrasound | |
Na et al. | Focused ultrasound for the treatment of obsessive-compulsive disorder | |
Yoo et al. | FUS-mediated image-guided neuromodulation of the brain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08828845 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08828845 Country of ref document: EP Kind code of ref document: A1 |